Haematological Malignancy Clinical Trial
Official title:
Prevalence of Adrenal Insufficiency Post-chemotherapy Adrenocorticotropia in Adult Hematology
A recent meta-analysis involving 3753 patients treated with corticosteroids notes that the population with the highest prevalence of biological IS (68%) is onco-hematology. However, it is also the least studied population with no recent and significant prevalence study. A recent multicenter study including patients followed up oncology who received dexamethasone for antiemetic purposes at cumulative doses well below the doses used in Hematology, objective a prevalence of biological IS estimated at 16% at 3 months from the start of chemotherapy. The introduction of a substitution had led to an objective improvement in the quality of life estimated by EORTC QLQ-C30.
A recent meta-analysis involving 3753 patients treated with corticosteroids notes that the population with the highest prevalence of biological IS (68%) is onco-hematology. However, it is also the least studied population with no recent and significant prevalence study. A recent multicenter study including patients followed up oncology who received dexamethasone for antiemetic purposes at cumulative doses well below the doses used in Hematology, objective a prevalence of biological IS estimated at 16% at 3 months from the start of chemotherapy. The introduction of a substitution had led to an objective improvement in the quality of life estimated by EORTC QLQ-C30. Expected results are prevalence rate of biological adrenal insufficiency between 15 and 20% with improvement of the quality of life in the 2 months post-chemotherapy by Hydrocortisone supplementation ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03978312 -
Nutrition Health Literacy of Cancer Patients and Their Support Networks.
|
||
| Recruiting |
NCT03750994 -
Economic Evaluation of Innovative Molecular Analyses in Onco-haematology
|
||
| Recruiting |
NCT04397705 -
Remote Monitoring of Cancer Patients With Suspected Covid-19
|
Phase 1 | |
| Recruiting |
NCT05678621 -
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Immunoglobulin Stopping or Extension
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05203809 -
Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies
|
||
| Active, not recruiting |
NCT03146468 -
Nivolumab for Relapsed or Residual Haematological Malignancies After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
| Recruiting |
NCT05298930 -
Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation
|
N/A | |
| Recruiting |
NCT05786716 -
DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT04673305 -
Cognitive Status Assessment In Elderly Patients With Active Treatment For Haematological Malignancies
|
N/A | |
| Recruiting |
NCT05722886 -
DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial) - Master Screening Protocol
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05768178 -
DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
|
Phase 2/Phase 3 | |
| Completed |
NCT03855969 -
Central Venous Access Device Removal in Cancer Patients
|
||
| Recruiting |
NCT04174053 -
Concordance Between 2 Means of Temperature Measure in Neutropenic Patients Hospitalized in Intensive Hematology Care Units
|
N/A | |
| Recruiting |
NCT05770544 -
DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05379738 -
Impact of Adapted Physical Activity on Patient's Recovery Following Allogeneic Stem Cell Transplantation for Hematological Malignancy
|
N/A | |
| Completed |
NCT04236063 -
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
|
||
| Recruiting |
NCT05695638 -
Proseq Cancer: Genomic Profiling in Patients With Incurable Cancer in Search for Targeted Treatment
|
||
| Recruiting |
NCT04298892 -
Integrated Multiomics and Multilevel Characterization of Haematological Disorders and Malignancies
|
||
| Withdrawn |
NCT04331483 -
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
|
N/A | |
| Recruiting |
NCT05770037 -
DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Teenage/Young Adults (TYA) and Paediatric Patients With ALK Positive Cancers
|
Phase 2/Phase 3 |